GLP1R and chronic kidney disease: Compared to non-users, GLP-1 receptor agonist users were younger (51.9 ± 13.8 vs 57.8 ± 16.5), more often female (60.1% vs 50.9%), had higher average BMI (36.2 ± 6.8 vs 31.4 ± 7.2), less chronic ischemic heart disease (7.7% vs 13.4%), less chronic kidney disease (8.4% vs 12.2%), and less heart failure (3.5% vs 7.1%).